These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19077095)

  • 1. Imatinib-induced pseudoporphyria.
    Timmer-de Mik L; Kardaun SH; Kramer MH; Hayes DP; Bousema MT
    Clin Exp Dermatol; 2009 Aug; 34(6):705-7. PubMed ID: 19077095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
    Breccia M; Carmosino I; Russo E; Morano SG; Latagliata R; Alimena G
    Eur J Haematol; 2005 Feb; 74(2):121-3. PubMed ID: 15654902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol.
    Hsieh HJ; Chan AL; Lin SJ
    Chemotherapy; 2009; 55(4):197-9. PubMed ID: 19439939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical management of patients with chronic myeloid leukemia receiving imatinib.
    Deininger MW; O'Brien SG; Ford JM; Druker BJ
    J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
    Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
    Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
    Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.
    Scheinfeld N
    J Drugs Dermatol; 2006 Mar; 5(3):228-31. PubMed ID: 16573254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
    Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
    Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib: new indication. Chronic myeloid leukaemia, first-line option: favourable findings to be confirmed.
    Prescrire Int; 2003 Dec; 12(68):216-8. PubMed ID: 14986692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
    Ault P; Kantarjian H; O'Brien S; Faderl S; Beran M; Rios MB; Koller C; Giles F; Keating M; Talpaz M; Cortes J
    J Clin Oncol; 2006 Mar; 24(7):1204-8. PubMed ID: 16446320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate-induced maculopapular drug rash.
    Dogra S; Kanwar AJ
    Natl Med J India; 2003; 16(5):285-6. PubMed ID: 14680290
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
    Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
    Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
    Severino G; Chillotti C; De Lisa R; Del Zompo M; Ardau R
    Ann Pharmacother; 2005 Jan; 39(1):162-4. PubMed ID: 15546944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 20. Livedoid skin reaction probably due to imatinib therapy.
    Martínez-González MC; del Pozo J; Yebra-Pimentel MT; Pérez M; Almagro M; Fonseca E
    Ann Pharmacother; 2007 Jan; 41(1):148-52. PubMed ID: 17190842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.